Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market...
Website: bio-rad.com



Growth: Bad revenue growth rate -6.7%, there is slowdown compared to average historical growth rates 2.8%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -12.2%

Profitability: LTM EBITDA margin is positive, +18.1%. On average the margin is decreasing unsteadily. Gross margin is high, +53.7%. In the last quarter the company did not beat the estimated EPS, -5.6%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.32 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 3.9% higher than minimum and 66.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.4x by EV / Sales multiple , the company can be 19.9% overvalued

Insiders: For the last 3 months insiders sold company shares on $1.8 mln (-0.018% of cap.)

Key Financials (Download financials)

Ticker: BIO
Share price, USD:  (+0.2%)279.83
year average price 343.65  


year start price 385.24 2023-05-06

max close price 422.63 2023-07-26

min close price 269.37 2023-10-30

current price 279.83 2024-05-04
Common stocks: 29 733 400

Dividend Yield:  0.0%
FCF Yield LTM: -2.2%
EV / LTM EBITDA: 16.3x
EV / EBITDA annualized: 14.9x
Last revenue growth (y/y):  -6.7%
Last growth of EBITDA (y/y):  -13.1%
Historical revenue growth:  2.8%
Historical growth of EBITDA:  5.0%
EV / Sales: 3.0x
Margin (EBITDA LTM / Revenue): 18.1%
Fundamental value created in LTM:
Market Cap ($m): 8 320
Net Debt ($m): -413
EV (Enterprise Value): 7 907
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-30Zacks Investment Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

2024-04-18Zacks Investment Research

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

2024-04-16Zacks Investment Research

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

2024-03-12Zacks Investment Research

Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

2024-02-16Zacks Investment Research

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

2024-02-05Zacks Investment Research

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

2023-12-20Zacks Investment Research

Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes

2023-10-27Zacks Investment Research

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

2023-10-26Seeking Alpha

Bio-Rad Laboratories, Inc. (BIO) Q3 2023 Earnings Call Transcript

2023-10-20Zacks Investment Research

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2024-02-16 2023-10-27 2023-08-04 2023-05-05 2023-02-17 2022-10-28
acceptedDate 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 681M 632M 681M 677M 730M 681M
costOfRevenue 315M 296M 319M 314M 333M 307M
grossProfit 366M 336M 362M 362M 397M 374M
grossProfitRatio 0.537 0.531 0.532 0.535 0.544 0.549
researchAndDevelopmentExpenses 62M 44M 65M 75M 66M 70M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 206M 201M 208M 226M 212M 211M
otherExpenses -65 000 20M 16M 50M 2M 0
operatingExpenses 268M 245M 273M 301M 278M 281M
costAndExpenses 583M 541M 591M 615M 612M 588M
interestIncome 17M 17M 17M 0 12M 8M
interestExpense 12M 12M 12M 12M 12M 12M
depreciationAndAmortization 53M 37M 36M 36M 42M 36M
ebitda 151M 149M 142M 148M 161M 129M
ebitdaratio 0.221 0.235 0.208 0.219 0.220 0.189
operatingIncome 98M 91M 90M 112M 119M 93M
operatingIncomeRatio 0.144 0.144 0.132 0.166 0.162 0.136
totalOtherIncomeExpensesNet 331M 59M -1 578M -28M 973M -302M
incomeBeforeTax 428M 137M -1 500M 85M 1 091M -209M
incomeBeforeTaxRatio 0.629 0.217 -2.203 0.125 1.494 -0.307
incomeTaxExpense 79M 31M -338M 16M 264M -45M
netIncome 350M 106M -1 162M 69M 828M -164M
netIncomeRatio 0.513 0.168 -1.706 0.102 1.133 -0.241
eps 12.150 3.650 -39.590 2.330 27.890 -5.520
epsdiluted 12.140 3.640 -39.590 2.320 27.780 -5.520
weightedAverageShsOut 29M 29M 29M 30M 30M 30M
weightedAverageShsOutDil 29M 29M 29M 30M 30M 30M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2024-02-16 2023-10-27 2023-08-04 2023-05-05 2023-02-17 2022-10-28
acceptedDate 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 404M 458M 390M 464M 434M 518M
shortTermInvestments 1 209M 1 307M 1 338M 1 393M 1 362M 1 338M
cashAndShortTermInvestments 1 613M 1 765M 1 728M 1 857M 1 796M 1 856M
netReceivables 501M 457M 492M 498M 495M 432M
inventory 781M 776M 777M 753M 719M 686M
otherCurrentAssets 154M 149M 142M 169M 148M 166M
totalCurrentAssets 3 048M 3 147M 3 139M 3 277M 3 158M 3 140M
propertyPlantEquipmentNet 724M 711M 688M 681M 680M 633M
goodwill 414M 407M 412M 408M 406M 400M
intangibleAssets 321M 314M 329M 328M 332M 325M
goodwillAndIntangibleAssets 734M 721M 740M 736M 739M 725M
longTermInvestments 7 698M 7 218M 7 311M 8 879M 8 831M 7 459M
taxAssets 1 475 495M 1 370M 1 402M 1 769 781M 0 0
otherNonCurrentAssets -1 475 401M -1 271M -1 302M -1 769 685M 95M 102M
totalNonCurrentAssets 9 251M 8 749M 8 839M 10 390M 10 344M 8 918M
otherAssets 0 0 0 0 0 0
totalAssets 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M
accountPayables 143M 267M 304M 335M 330M 335M
shortTermDebt 41M 476 000 476 000 519 000 465 000 448 000
taxPayables 35 759M 104M 74M 51M 32M 29M
deferredRevenue 35 759M -112M 74M 0 52M 1 484 606M
otherCurrentLiabilities -35 420M 403M 203M 254M 186M -1 484 371M
totalCurrentLiabilities 523M 558M 582M 590M 569M 571M
longTermDebt 1 189M 1 199M 1 198M 1 198M 1 198M 1 197M
deferredRevenueNonCurrent 175M -1 370M -1 402M 0 1 770 481M 0
deferredTaxLiabilitiesNonCurrent 1 475M 1 370M 1 402M 1 770M 1 770M 1 485M
otherNonCurrentLiabilities 195M 1 723M 1 751M 346M -1 770 131M -1 481 907M
totalNonCurrentLiabilities 3 035M 2 922M 2 949M 3 314M 3 318M 3 034M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 175M 167M 147M 183M 190M 192M
totalLiabilities 3 558M 3 480M 3 531M 3 904M 3 886M 3 605M
preferredStock 0 0 0 0 0 0
commonStock 3000.000 3000.000 3000.000 3000.000 3000.000 3000.000
retainedEarnings 9 261M 8 911M 8 805M 9 967M 9 898M 9 047M
accumulatedOtherComprehensiveIncomeLoss -336M -498M -373M -408M -467M -845M
othertotalStockholdersEquity -183M 3M 15M 205M 184M 252M
totalStockholdersEquity 8 741M 8 416M 8 447M 9 764M 9 615M 8 454M
totalEquity 8 741M 8 416M 8 447M 9 764M 9 615M 8 454M
totalLiabilitiesAndStockholdersEquity 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M
totalInvestments 8 907M 8 525M 8 649M 10 271M 8 843M 8 797M
totalDebt 1 406M 1 199M 1 199M 1 199M 1 198M 1 198M
netDebt 1 002M 741M 809M 734M 764M 680M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2024-02-16 2023-10-27 2023-08-04 2023-05-05 2023-02-17 2022-10-28
acceptedDate 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 350M 106M -1 162M 69M 833M -164M
depreciationAndAmortization 53M 37M 36M 36M 40M 33M
deferredIncomeTax 75M -16M -13M -13 900 0 0
stockBasedCompensation 16M 16M 13M 17M 18M 16M
changeInWorkingCapital -94M 360M -16M -39M -63M -100M
accountsReceivables -20M 26M 7M -1M -43M 1M
inventory 15M -6M -25M -30M -8M -48M
accountsPayables 21M -38M -43M 8M -25M -27M
otherWorkingCapital -110M 378M 45M -16M 12M -27M
otherNonCashItems -319M -406M 1 241M 16M -738M 224M
netCashProvidedByOperatingActivities 81M 98M 98M 98M 90M 8M
investmentsInPropertyPlantAndEquipment -42M -44M -35M -36M -47M -24M
acquisitionsNet 3M 44M 35M 36M 46M -101M
purchasesOfInvestments -152M -196M -138M -204M -253M -329M
salesMaturitiesOfInvestments -239M 231M 201M 169M 231M 369M
otherInvestingActivites 502M -44M -35M -36M -46M 6000.000
netCashUsedForInvestingActivites 72M -10M 28M -70M -69M -85M
debtRepayment -118 000 -118 000 -116 000 -115 000 -143 000 -113 000
commonStockIssued 4M 5M 0 0 17 560M 0
commonStockRepurchased -200M -21M 0 0 -91M -129M
dividendsPaid 0 0 0 -14 662M -47 432M -30M
otherFinancingActivites 85 434M -5M -203M 14 666M 29 876M 151M
netCashUsedProvidedByFinancingActivities -201M -27M -203M 4M -87M -9M
effectOfForexChangesOnCash -7M 6M 3M -2M -18M 8M
netChangeInCash -54M 68M -74M 30M -84M -79M
cashAtEndOfPeriod 404M 458M 390M 465M 435M 518M
cashAtBeginningOfPeriod 458M 390M 465M 435M 518M 597M
operatingCashFlow 81M 98M 98M 98M 90M 8M
capitalExpenditure -42M -44M -35M -36M -47M -24M
freeCashFlow 39M 54M 63M 62M 43M -17M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-18 13:00 ET
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
2024-04-10 20:15 ET
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
2024-03-20 12:30 ET
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
2024-02-22 21:30 ET
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
2024-02-15 21:15 ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
2024-01-24 22:00 ET
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
2024-01-02 21:15 ET
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
2023-10-26 20:15 ET
Bio-Rad Reports Third-Quarter 2023 Financial Results
2023-10-05 12:30 ET
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
2023-08-28 20:15 ET
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference
2023-08-03 20:15 ET
Bio-Rad Reports Second-Quarter 2023 Financial Results
2023-07-26 20:15 ET
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
2023-07-20 20:30 ET
Bio-Rad Announces New Share Repurchase Program
2023-07-10 20:30 ET
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
2023-07-10 13:00 ET
Bio-Rad Publishes Corporate Sustainability Report for 2022
2023-06-01 12:00 ET
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
2023-05-08 12:00 ET
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
2023-05-04 20:15 ET
Bio-Rad Reports First-Quarter 2023 Financial Results
2023-04-12 20:11 ET
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
2023-02-17 14:00 ET
Bio-Rad to Participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference
2023-02-16 21:05 ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
2023-02-08 13:00 ET
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
2023-01-06 14:00 ET
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
2023-01-04 14:00 ET
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
2022-10-31 12:30 ET
Bio-Rad To Participate in Fireside Chat During Credit Suisse’s 31st Annual Healthcare Conference
2022-10-27 20:05 ET
Bio-Rad Reports Third-Quarter 2022 Financial Results
2022-10-17 12:30 ET
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
2022-08-03 20:15 ET
Bio-Rad Acquires Curiosity Diagnostics
2022-07-28 20:17 ET
Bio-Rad Reports Second-Quarter 2022 Financial Results
2022-07-18 20:15 ET
Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022
2022-06-27 12:00 ET
Bio-Rad Publishes Corporate Sustainability Report
2022-04-28 20:15 ET
Bio-Rad Reports First-Quarter 2022 Financial Results
2022-04-18 12:00 ET
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
2022-03-02 22:51 ET
Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering
2022-02-25 14:15 ET
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day
2022-02-10 21:15 ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results
2022-02-02 21:15 ET
Bio-Rad to Host Investor Day on February 25
2022-01-25 13:00 ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2021 Financial Results, Thursday, February 10, 2022
2022-01-05 21:15 ET
Bio-Rad to Participate in Fireside Chat During the 40th Annual J.P. Morgan Healthcare Conference on January 11
2021-12-16 13:00 ET
Bio-Rad Appoints Simon May Executive Vice President and Life Science Group President
2021-10-28 20:15 ET
Bio-Rad Reports Third-Quarter 2021 Financial Results
2021-10-15 12:00 ET
Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021
2021-08-31 12:00 ET
Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference
2021-07-29 20:15 ET
Bio-Rad Reports Second-Quarter 2021 Financial Results
2021-07-27 16:27 ET
Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations
2021-07-27 10:30 ET
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
2021-07-14 20:15 ET
Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021
2021-06-30 21:00 ET
Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products
2021-06-21 12:00 ET
Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing
2021-05-20 12:30 ET
Bio-Rad to Participate at Jefferies Virtual Healthcare Conference
2021-04-29 20:15 ET
Bio-Rad Reports First-Quarter 2021 Financial Results
2021-04-15 12:30 ET
Bio-Rad to Report First-Quarter 2021 Financial Results, Thursday, April 29, 2021
2021-03-05 21:16 ET
Bio-Rad to Participate in Barclays Global Healthcare Conference 2021
2021-02-22 21:15 ET
Bio-Rad to Participate in Citi’s 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
2021-02-11 21:20 ET
Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results
2021-01-25 21:15 ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2020 Financial Results Thursday, February 11, 2021
2021-01-08 13:30 ET
Bio-Rad to Participate in Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11
2020-12-10 22:33 ET
Bio-Rad Provides Outlook Through 2023
2020-10-29 20:15 ET
Bio-Rad Reports Third-Quarter 2020 Financial Results
2020-10-19 12:30 ET
Bio-Rad to Report Third-Quarter 2020 Financial Results, Thursday, October 29, 2020
2020-08-04 12:30 ET
The United States Court of Appeals for the Federal Circuit Affirms That 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages
2020-07-30 20:15 ET
Bio-Rad Reports Second-Quarter 2020 Financial Results
2020-07-16 00:01 ET
Bio-Rad to Report Second-Quarter 2020 Financial Results, Thursday, July 30, 2020
2020-05-06 20:15 ET
Bio-Rad Reports First-Quarter 2020 Financial Results
2020-05-04 23:27 ET
Bio-Rad Receives FDA Emergency Use Authorization for Droplet Digital PCR SARS-CoV-2 Test Kit
2020-04-30 20:51 ET
Bio-Rad’s SARS-CoV-2 (COVID-19) Serology Test Granted FDA Emergency Use Authorization, the First Total Antibody Test to Receive EUA from the FDA
2020-04-22 20:25 ET
Bio-Rad to Report First-Quarter 2020 Financial Results Wednesday, May 6, 2020
2020-04-21 12:30 ET
Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity
2020-04-09 12:30 ET
Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider
2020-04-07 12:30 ET
Bio-Rad Announces the Launch of a Serology Assay to Detect Coronavirus (COVID-19) Antibodies
2020-03-19 21:30 ET
New Studies Find Bio-Rad’s QX200 Droplet Digital PCR System Can Detect COVID-19 With Greater Sensitivity and Precision Than Other Existing Molecular Tests
2020-03-18 23:24 ET
Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing
2020-03-12 23:30 ET
Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing
2020-02-25 21:15 ET
Bio-Rad to Present at Barclays Global Healthcare Conference 2020 on March 10
2020-02-13 21:15 ET
CORRECTING and REPLACING Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results
2020-02-04 02:37 ET
Bio-Rad to Report Fourth-Quarter and Full-Year 2019 Financial Results Thursday, February 13, 2020
2020-01-06 13:30 ET
Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President
2020-01-02 21:15 ET
Bio-Rad to Participate at the 38th Annual J.P. Morgan Healthcare Conference on January 13
2019-12-23 13:30 ET
The International Trade Commission Issues Final Decision Affirming 10X Genomics Infringement of Three of Bio-Rad’s Patents
2019-12-13 21:52 ET
Bio-Rad Makes Progress Recovering from Recent Ransomware Attack
2019-04-15 23:03 ET
Bio-Rad to Report First-Quarter 2019 Financial Results
2019-04-08 20:15 ET
Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market
2019-04-02 21:00 ET
Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer

SEC forms

Show financial reports only

SEC form 10
2024-02-16 00:00 ET
Bio-Rad Laboratories published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Bio-Rad Laboratories published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Bio-Rad Laboratories reported for 2023 q4
SEC form 10
2023-10-27 16:31 ET
Bio-Rad Laboratories published news for 2023 q3
SEC form 10
2023-10-27 00:00 ET
Bio-Rad Laboratories published news for 2023 q3
SEC form 8
2023-10-26 16:17 ET
Bio-Rad Laboratories reported for 2023 q3
SEC form 10
2023-08-04 16:31 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-08-03 16:19 ET
Bio-Rad Laboratories reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-07-20 16:31 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-06-05 08:45 ET
Bio-Rad Laboratories published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Bio-Rad Laboratories published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Bio-Rad Laboratories reported for 2023 q1
SEC form 10
2023-02-17 00:00 ET
Bio-Rad Laboratories reported for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Bio-Rad Laboratories reported for 2022 q4
SEC form 10
2022-10-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Bio-Rad Laboratories reported for 2022 q3
SEC form 10
2022-07-29 00:00 ET
Bio-Rad Laboratories reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
Bio-Rad Laboratories reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q1
SEC form 10
2022-02-11 00:00 ET
Bio-Rad Laboratories published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
Bio-Rad Laboratories published news for 2021 q4
SEC form 10
2021-10-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Bio-Rad Laboratories published news for 2021 q3
SEC form 10
2021-07-30 00:00 ET
Bio-Rad Laboratories published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
Bio-Rad Laboratories published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q1